Rheumatoid Arthritis Drugs Market is Expected to Expand at a CAGR of 2.96% from 2018 to 2026

1
Drug Type - Disease-modifying Anti-rheumatic
Drugs (DMARDs), Non-steroidal Anti-inflammatory
Drugs (NSAIDs), Corticosteroids, Biologic
Response Modifiers (Biologics) Distribution
Channel - Hospital Pharmacy, Retail Pharmacy,
Online PharmacyForecast From 2018 - 2026
Rheumatoid Arthritis Drugs Market
2
Table of Content
Sr. No. Content
Chapter 1 Preface
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary
Chapter 4 Market Overview
Chapter 5 Market Outlook
Chapter 6 Global Rheumatoid Arthritis Drugs Market Analysis, by Drug Type
Chapter 7 Global Rheumatoid Arthritis Drugs Market Analysis, by Distribution Channel
Chapter 8 Global Rheumatoid Arthritis Drugs Market Analysis, by Region
Chapter 9 North America Rheumatoid Arthritis Drugs Market Analysis
Chapter 10 Europe Rheumatoid Arthritis Drugs Market Analysis
Chapter 11 Asia Pacific Rheumatoid Arthritis Drugs Market Analysis
Chapter 12 Latin America Rheumatoid Arthritis Drugs Market Analysis
Chapter 13 Middle East Africa Rheumatoid Arthritis Drugs Market Analysis
Chapter 14 Competitive Landscape
3
Snapshot

• Rheumatoid arthritis is an autoimmune disorder
  that causes pain and inflammation in the joints.
  In this disease, the immune system mistakenly
  affects the joints, causing inflammation and pain
  in the joints throughout the body.
• Rise in geriatric population, high prevalence of
  rheumatoid arthritis, and increase in patient
  preference for biological origin drugs are major
  drivers of the global rheumatoid arthritis drugs
  market.
• global rheumatoid arthritis drugs market can be
  segmented based on drug type, distribution
  channel, and geography.

4
(No Transcript)
5
Reports Highlights

• Global rheumatoid arthritis drugs market is
  expected to expand at a CAGR of 2.96 from 2018
  to 2026. In 2016, the global market was valued at
  US 19597.43 Mn.
• Key Players Pfizer, Inc., Novartis AG, Sanofi
  S.A., F. Hoffmann-La Roche Ltd., Merck Co.,
  Inc., Bristol-Myers Squibb Company, and Eli Lilly
  and Company.

Request Sample
6
(No Transcript)